SOURCE: Biophan Technologies, Inc.

January 23, 2008 07:00 ET

Biophan Names Stan Yakatan as Chairman of the Board

PITTSFORD, NY--(Marketwire - January 23, 2008) - Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced that the company has named Mr. Stan Yakatan as chairman of the board of directors.

Mr. Yakatan has served on Biophan's Board of Directors since 2006 and is also the founder, chairman, and CEO of Katan Associates, a global strategic consulting firm and corporate finance advisory group focused on life sciences.

Mr. Yakatan has completed and advised on numerous acquisitions and corporate finance transactions, raising in excess of one billion dollars in the public and private capital financing markets. He is also a frequent speaker at financial and biotechnology conferences throughout the world, and serves as the strategic advisor to the State Government of Victoria, Australia. Mr. Yakatan has founded or co-founded more than 15 companies in the United States, Canada, Israel, France and Germany.

Mr. Yakatan currently serves as chairman of Grant Life Sciences, Inc., a Los Angeles-based company focused on the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancer. He facilitated a public listing for Grant Life Sciences, and has established the development of 2 products designed to replace and augment the Pap Smear, as cervical cancer screening represents a market of more than 1.7 billion women worldwide.

About Biophan Technologies, Inc.

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 68% interest in Myotech with rights to acquire additional equity, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expect, or believe may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information

  • Contact:
    Carolyn Hotchkiss
    Communications Manager
    Biophan Technologies, Inc.
    (585) 267-4800
    Email Contact